Curacle Co

Curacle Co Intangible Assets

The Intangible Assets of Curacle Co (365270.KQ) as of Nov 3, 2026 is 321.62 M KRW. In the previous year, Intangible Assets was 251.41 M KRW — a change of 27.93% (higher).

Intangible Assets

321.62 MKRW

YoY

27.93%

Last updated:

Intangible Assets of Curacle Co is 2022 321.62 M KRW. Intangible Assets of Curacle Co was 2021 251.41 M KRW. It decreases by 27.93% higher compared to the previous year.

The Curacle Co Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2018
230.62 M KRW
Jan 1, 2019
205.35 M KRW
Jan 1, 2020
172.23 M KRW
Jan 1, 2021
251.41 M KRW
Jan 1, 2022
321.62 M KRW
The Curacle Co Intangible Assets history
YEARIntangible AssetsYoY
321.62 MKRW+27.93%
251.41 MKRW+45.97%
172.23 MKRW-16.13%
205.35 MKRW-10.96%
230.62 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Curacle Co Stock analysis

What does Curacle Co do? Curacle Co., Ltd. generates revenue through the research and development of synthetic drugs CU06-RE, CU01, and natural drug CU03, targeting intractable vascular diseases. These drugs address diabetic macular edema (DME), diabetic nephropathy (DN), and wet age-related macular degeneration (wet AMD). The company leverages its SOLVADYS platform technology, a specialized platform for developing vascular endothelial dysfunction blockers, to advance its drug development pipeline. The primary buyers of Curacle's products are pharmaceutical companies and medical institutions seeking innovative treatments for vascular-related conditions. The company focuses on intractable vascular diseases, a niche segment where current treatments are limited, positioning its drugs as novel solutions. SOLVADYS platform technology is utilized by the company internally to enhance its research capabilities and streamline drug development processes. Curacle's business model centers on developing proprietary drug candidates and platform technology, with revenue streams derived from potential future licensing agreements, partnerships, or direct sales of its drug candidates. The company's focus on rare and complex vascular diseases ensures a targeted market segment with high unmet medical needs, attracting interest from specialized healthcare providers and pharmaceutical developers. Curacle Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curacle Co stock

Intangible Assets of Curacle Co is 321.62 M KRW in 2022.

Intangible Assets of Curacle Co changed from 251.41 M KRW to 321.62 M KRW, representing a 27.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Curacle Co since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Curacle Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Curacle Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Curacle Co